Clinical Trial Update: PROMISE Study: An Evaluation of an Implantable Continuous Glucose Sensor up to 180 Days [NA]

View source ↗

Summary

A clinical trial update for Senseonics' PROMISE study evaluating an implantable continuous glucose sensor over up to 180 days; the trial is completed and result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus
• Type 2 Diabetes Mellitus

Snippet

Sponsor: Senseonics, Inc. | Conditions: Diabetes Mellitus, Diabetes Mellitus, Type 1 | NA | Status: COMPLETED | Results posted: 2024-08-20